Parallax Volatility Advisers
PGNX

Parallax Volatility Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Parallax Volatility Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-535,000
Closed -$2.25M – 4463
2018
Q4 		$2.25M Sell
535,000
-160,000
-23% -$815K ﹤0.01% 1021
2018
Q3 		$4.36M Buy
695,000
+670,000
+2,680% +$5.15M 0.01% 765
2018
Q2 		$201K Buy
+25,000
New +$191K ﹤0.01% 1402

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Parallax Volatility Advisers's PGNX Position: Q1 2019 in Review

Parallax Volatility Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 478,657 shares — an estimated $2.01M sold.

Parallax Volatility Advisers first reported a position in PGNX in Q3 2017 and held it in 5 quarters. The position peaked at $2.83M in Q3 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Parallax Volatility Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 478,657 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $2.01M.
  • Parallax Volatility Advisers first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Progenics Pharmaceuticals Inc position peaked at $2.83M in Q3 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Parallax Volatility Advisers's 13F filing for Q1 2019, filed 15 May 2019.